All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

At present, more than 750 million people throughout the world are at risk for infection with liver flukes, with an endemic concentration in southeast Asia and the western Pacific region\[[@pone.0132673.ref001]\]. The most important liver fluke species include *Clonorchis sinensis*, *Fasciola* spp. and *Opisthorchis* spp.\[[@pone.0132673.ref002]\]. The infectious metacercarial cyst stage is found in the meat of fish and shrimp as well as on the surfaces of water plants\[[@pone.0132673.ref003]\]. Once ingested, the metacercaria excysts in the duodenum, and the juvenile worm ascends the biliary tract through the ampulla of Vater\[[@pone.0132673.ref003]\]. The metabolites and mechanical stimulation of the liver fluke result in proliferation and inflammation in the epithelia of the biliary tracts as well as fibrosis and even cholangiocarcinoma\[[@pone.0132673.ref002], [@pone.0132673.ref004]\]. In humans, early and light infections may be asymptomatic or mild and are usually neglected. Infection by a large number of worms results in serious inflammation and leads to biliary tract obstruction, bile flux block and icterus\[[@pone.0132673.ref004]\]. However, the long-lived flukes cause chronic inflammation, which may be severe\[[@pone.0132673.ref005]\]. During chronic infection resulting from protracted episodes of re-infection over time, hepatic cells around the biliary ducts become denaturalized and putrescent, resulting in hepatic tissue atrophy and hepatocirrhosis\[[@pone.0132673.ref004], [@pone.0132673.ref006]\]. According to Keiser and Utzinger's study, the global burden of food-born trematodiasis is 665,332 (479,496--859,051) DALYs (disability-adjusted life years). Moreover, they reported that food-borne trematode infections are among the most neglected of the so-called neglected tropical diseases\[[@pone.0132673.ref007], [@pone.0132673.ref008]\]. The awareness of liver fluke infection as a public health problem is insufficient because this infection impacts millions of people with severe morbidity and continues to emerge and expand. The increased infection rate of liver flukes may be due to factors such as the improved transportation and distribution systems to bring these aquatic foods to local and international markets\[[@pone.0132673.ref002], [@pone.0132673.ref008]\]. For example, in China, the current clonorchiasis rate is three times higher than that in the past decade\[[@pone.0132673.ref009], [@pone.0132673.ref010]\]. Findings of studies investigating the association between liver fluke infection and various hepatobiliary pathological changes have not been consistent, and systematic reviews and meta-analyses exploring the association have been even more limited. The present paper is based on a systematic review from cross-regional cohort studies and case-control studies to investigate the association between liver fluke infection and hepatobiliary pathological changes. This study will provide a more objective and comprehensive conclusion on this subject.

Materials and Methods {#sec006}
=====================

Search strategy {#sec007}
---------------

The study was performed using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses)\[[@pone.0132673.ref011]\]. The PRISMA statement is available in the supplementary data ([S1 Table](#pone.0132673.s001){ref-type="supplementary-material"}). Relevant literature that reported an association between liver fluke infection and hepatobiliary pathological changes was identified and screened from databases, including PubMed, Cochrane, Clinical Evidence, Trip Database, Clinical Trials, Current Controlled Trials, Web of Science, the China National Knowledge Infrastructure (CNKI) database, and the Wanfang academic journal full-text database. The following Medical Subject Heading (MeSH) terms were used individually and in combination in the search: "Fasciola hepatica," "Clonorchis sinensis," "Opisthorchis," "Case-Control Studies," "Cohort Studies," "Cross-Sectional Studies," "Hepatobiliary pathological changes," "Cholangitis," "Cholecystitis," "Cholelithiasis," "Cirrhosis," "Hepatocellular Carcinoma" and "Cholangiocarcinoma." The literature search was not limited by language or geographical region. The references in all of the retrieved articles were reviewed to search for additional relevant studies.

Criteria for inclusion and exclusion {#sec008}
------------------------------------

The inclusion criteria were as follows: (1) published full text available; (2) an observational study (a cohort study or a case-control study); (3) sufficient data reported to calculate the odds ratio (OR) with its 95% confidence interval (CI); and (4) the diagnosis of liver fluke infection based on (a) microscopy of liver fluke eggs in stool samples; (b) detection of worm-specific antibodies in serum samples or worm-specific antigens in serum or stool samples; (c) skin test with an intradermal injection of diluted crude live fluke antigen in veronal-buffered saline\[[@pone.0132673.ref012]\]; (d) observation of liver fluke eggs or parasites from bile, gallstones or intramural stones; (e) detection of diffuse dilatation of intrahepatic bile ducts in abdominal computed tomography (CT) or cholangiography; (f) results of molecular techniques such as polymerase chain reaction (PCR); or (g) history of liver fluke infection that could be confirmed by medical records. Studies were excluded if they were (1) comments, congresses, abstracts, reviews, or editorials without raw data or control subjects or (2) studies that included fewer than 10 participants.

Data extraction {#sec009}
---------------

The following information was independently extracted from all of the included studies: the name of the first author, publication year, country or geographical area, liver fluke species, diagnostic methods for liver fluke infection, sample size, the number of the exposure or outcome of interest for case-control or cohort studies, respectively, and the quality of each study.

Quality assessment {#sec010}
------------------

The quality of all of the included studies was assessed using The Newcastle-Ottawa Scale (NOS) ([S2 Table](#pone.0132673.s002){ref-type="supplementary-material"}). This scale involves a "star system" in which a study is judged on three broad perspectives: the selection of the study groups, the comparability of the groups and the ascertainment of either the exposure or outcome of interest for case-control or cohort studies, respectively. Studies having more stars are considered to be of higher quality.

Statistical analysis {#sec011}
--------------------

Statistical heterogeneity among studies was calculated using the χ^2^ test, P values, and I^2^ statistics\[[@pone.0132673.ref013]\]. A random-effects model was used to estimate the overall relative risk (RR) or overall odds ratio (OR) when heterogeneity was significant (Q: P\<0.1, or I^2^\>50%); if the reverse was true, a fixed-effects model was used (Q: P\>0.1, or I^2^\>50%). The overall RRs and ORs and their 95% CIs were estimated (P\<0.05 was considered significant), and forest plots were generated for each disease associated with liver fluke infection. A sensitivity analysis was conducted, and publication bias was evaluated using funnel plots\[[@pone.0132673.ref014]\]. Meta-regression analyses were generated to explore possible sources of heterogeneity (adjusted R^2^\>50% and P\<0.05 were considered significant.) \[[@pone.0132673.ref015], [@pone.0132673.ref016]\], such as geographical area, decade of publication, liver fluke species, diagnostic methods and study sample size. Linear trend analyses were performed to determine the relationship between infection intensity and incidences of hepatobiliary pathological changes. Risk estimates, tests of heterogeneity, sensitivity calculations and publication bias analyses were performed using the Review Manager software, version 5.3; meta-regression analysis was performed using the Stata software, version 11.0 (Stata Corporation, College Station, TX, USA); and linear trend analyses were performed using IBM SPSS Statistics 20.0.

Results {#sec012}
=======

Study characteristics {#sec013}
---------------------

A comprehensive search of databases provided 1881 potentially relevant citations, of which 10 cohort studies and 26 case-control studies met the study criteria and were included in the meta-analysis ([Fig 1](#pone.0132673.g001){ref-type="fig"}). Among the included studies, 14 were from mainland China\[[@pone.0132673.ref017]--[@pone.0132673.ref030]\], 1 was from Hong Kong\[[@pone.0132673.ref031]\], 2 were from Taiwan\[[@pone.0132673.ref032], [@pone.0132673.ref033]\], 7 were from Korea\[[@pone.0132673.ref034]--[@pone.0132673.ref040]\], and 11 were from Thailand\[[@pone.0132673.ref041]--[@pone.0132673.ref051]\]. The characteristics of the included studies with their quality are shown in Tables [1](#pone.0132673.t001){ref-type="table"} and [2](#pone.0132673.t002){ref-type="table"}.

![Flow chart of study selection.](pone.0132673.g001){#pone.0132673.g001}

10.1371/journal.pone.0132673.t001

###### Characteristics of included cohort studies on liver fluke infection and the risk of hepatobiliary pathological changes.

![](pone.0132673.t001){#pone.0132673.t001g}

                                                                                                                            Infected   Uninfected   Quality                          
  ------------------------------ ------------ ------ ---------- -------------------------- ------------------------ ------- ---------- ------------ --------- ------- ----- --- ---- ----------------------------
  Cholangitis or Cholecystitis   Zhu SH       1982   China      *Clonorchis sinensis*      Pathologic examination   17603   381        2214         126       15389   ★     ★   ★    \[[@pone.0132673.ref017]\]
                                 Mairiang E   1992   Thailand   *Opisthorchis viverrini*   Stool microscopy         95      27         71           4         24      ★★★   ★   ★    \[[@pone.0132673.ref041]\]
                                 Chen ZZ      1997   China      *Clonorchis sinensis*      Stool microscopy         5230    79         1315         31        3915    ★★★   ★   ★    \[[@pone.0132673.ref018]\]
  Cholelithiasis                 Zhu SH       1982   China      *Clonorchis sinensis*      Pathologic examination   17603   93         2214         46        15389   ★     ★   ★    \[[@pone.0132673.ref017]\]
                                 Hou MF       1989   Taiwan     *Clonorchis sinensis*      Liver fluke history      1091    89         947          8         144     ★★★   ★   ★★   \[[@pone.0132673.ref032]\]
                                 Mairiang E   1992   Thailand   *Opisthorchis viverrini*   Stool microscopy         95      6          71           0         24      ★★★   ★   ★    \[[@pone.0132673.ref041]\]
                                 Choi MS      2005   China      *Clonorchis sinensis*      Stool microscopy         1384    279        1215         9         169     ★★★   ★   ★    \[[@pone.0132673.ref019]\]
                                 Huang MH     2005   Taiwan     *Clonorchis sinensis*      Serologic test           131     12         47           46        84      ★★★   ★   ★    \[[@pone.0132673.ref033]\]
                                 Kim HG       2009   Korea      *Clonorchis sinensis*      Several evidence lines   3080    45         396          340       2684    ★★★   ★   ★    \[[@pone.0132673.ref034]\]
                                 Zhang X      2010   China      *Clonorchis sinensis*      Several evidence lines   1326    352        682          78        644     ★★★   ★   ★    \[[@pone.0132673.ref020]\]
                                 Luo XB       2013   China      *Clonorchis sinensis*      Pathologic examination   340     49         153          30        187     ★★★   ★   ★    \[[@pone.0132673.ref021]\]
  Cirrhosis                      Zhu SH       1982   China      *Clonorchis sinensis*      Pathologic examination   17603   128        2214         94        15389   ★     ★   ★    \[[@pone.0132673.ref017]\]
                                 Huang MH     2005   Taiwan     *Clonorchis sinensis*      Serologic test           131     3          47           3         84      ★★★   ★   ★    \[[@pone.0132673.ref033]\]
                                 Mairiang E   2012   Thailand   *Opisthorchis viverrini*   Stool microscopy         3359    182        404          656       2955    ★★★   ★   ★★   \[[@pone.0132673.ref042]\]
  Cholangiocarcinoma             Zhu SH       1982   China      *Clonorchis sinensis*      Pathologic examination   17603   5          2214         0         15389   ★     ★   ★    \[[@pone.0132673.ref017]\]
                                 Mairiang E   1992   Thailand   *Opisthorchis viverrini*   Stool microscopy         95      2          71           0         24      ★★★   ★   ★    \[[@pone.0132673.ref041]\]
                                 Huang MH     2005   Taiwan     *Clonorchis sinensis*      Serologic test           131     1          47           0         84      ★★★   ★   ★    \[[@pone.0132673.ref033]\]

10.1371/journal.pone.0132673.t002

###### Characteristics of included case-control studies on liver fluke infection and the risk of hepatobiliary pathological changes.

![](pone.0132673.t002){#pone.0132673.t002g}

                                                                                                                                  Case   Control   Quality                          
  ------------------------------ ---------------- ------ ----------- -------------------------- -------------------------- ------ ------ --------- --------- ------ ----- ---- ---- ----------------------------
  Cholangitis or Cholecystitis   Elkins DB        1990   Thailand    *Opisthorchis viverrini*   Stool microscopy           53     10     12        28        41     ★★    ★    ★★   \[[@pone.0132673.ref043]\]
                                 Itoh M           1994   Thailand    *Opisthorchis viverrini*   Serologic test             69     29     49        0         20     ★★★   ★    ★★   \[[@pone.0132673.ref044]\]
                                 Zheng ZX         1997   China       *Clonorchis sinensis*      Serologic test             53     6      14        1         39     ★     ★    ★★   \[[@pone.0132673.ref022]\]
                                 Chen MF          2001   China       *Clonorchis sinensis*      Serologic test             117    12     38        1         79     ★     ★    ★★   \[[@pone.0132673.ref023]\]
  Cholelithiasis                 Elkins DB        1990   Thailand    *Opisthorchis viverrini*   Stool microscopy           47     5      6         28        41     ★★    ★    ★★   \[[@pone.0132673.ref043]\]
                                 Zheng ZX         1997   China       *Clonorchis sinensis*      Serologic test             53     6      14        1         39     ★     ★    ★★   \[[@pone.0132673.ref022]\]
                                 Chen MF          2001   China       *Clonorchis sinensis*      Serologic test             117    12     38        1         79     ★     ★    ★★   \[[@pone.0132673.ref023]\]
                                 Huang MH         2005   Taiwan      *Clonorchis sinensis*      Serologic test             252    9      131       1         121    ★★    ★    ★★   \[[@pone.0132673.ref033]\]
                                 Choi D           2008   Korea       *Clonorchis sinensis*      Stool microscopy           134    3      67        1         67     ★★★   ★    ★★   \[[@pone.0132673.ref035]\]
                                 Choi D           2008   Korea       *Clonorchis sinensis*      Serologic test             134    4      67        1         67     ★★★   ★★   ★★   \[[@pone.0132673.ref035]\]
                                 Choi D           2008   Korea       *Clonorchis sinensis*      Radiological examination   134    10     67        16        67     ★★★   ★★   ★★   \[[@pone.0132673.ref035]\]
  Cirrhosis                      Zheng ZX         1997   China       *Clonorchis sinensis*      Serologic test             49     2      10        1         39     ★     ★    ★★   \[[@pone.0132673.ref022]\]
                                 Chen MF          2001   China       *Clonorchis sinensis*      Serologic test             129    12     50        1         79     ★     ★    ★★   \[[@pone.0132673.ref023]\]
                                 Sripa B          2009   Thailand    *Opisthorchis viverrini*   Stool microscopy           328    46     200       20        128    ★★★   ★★   ★★   \[[@pone.0132673.ref045]\]
  Hepatocellular carcinoma       Chen HN          1994   China       *Clonorchis sinensis*      Liver fluke history        246    9      123       2         123    ★★★   ★★   ★    \[[@pone.0132673.ref024]\]
                                 Shin HR          1996   Korea       *Clonorchis sinensis*      Stool microscopy           526    36     176       44        350    ★★    ★★   ★★   \[[@pone.0132673.ref036]\]
                                 Shin HR          1996   Korea       *Clonorchis sinensis*      Liver fluke history        609    19     203       21        406    ★★    ★★   ★    \[[@pone.0132673.ref036]\]
                                 Zheng ZX         1997   China       *Clonorchis sinensis*      Serologic test             111    16     72        1         39     ★     ★    ★★   \[[@pone.0132673.ref022]\]
                                 Chen MF          2001   China       *Clonorchis sinensis*      Serologic test             98     4      19        1         79     ★     ★    ★★   \[[@pone.0132673.ref023]\]
                                 Tan SK           2007   China       *Clonorchis sinensis*      Liver fluke history        1000   85     500       13        500    ★     ★    ★    \[[@pone.0132673.ref025]\]
                                 Tan SK           2008   China       *Clonorchis sinensis*      Serologic test             944    73     444       12        500    ★     ★    ★★   \[[@pone.0132673.ref026]\]
  Cholangiocarcinoma             Gibson RB        1971   Hong Kong   *Clonorchis sinensis*      Stool microscopy           1401   11     17        310       1384   ★     \-   \-   \[[@pone.0132673.ref031]\]
                                 Kim YI           1974   Korea       *Clonorchis sinensis*      Stool microscopy           1402   21     54        120       1348   ★★    \-   \-   \[[@pone.0132673.ref037]\]
                                 Chung CS         1976   Korea       *Clonorchis sinensis*      Stool microscopy           595    19     36        88        559    ★★    \-   \-   \[[@pone.0132673.ref038]\]
                                 Kurathong S      1985   Thailand    *Opisthorchis viverrini*   Stool microscopy           560    19     25        389       535    ★★    \-   \-   \[[@pone.0132673.ref046]\]
                                 Elkins DB        1990   Thailand    *Opisthorchis viverrini*   Stool microscopy           49     8      8         28        41     ★★    ★    ★★   \[[@pone.0132673.ref043]\]
                                 Parkin DM        1991   Thailand    *Opisthorchis viverrini*   Stool microscopy           202    43     101       9         101    ★     ★★   \-   \[[@pone.0132673.ref047]\]
                                 Elkins H         1994   Thailand    *Opisthorchis viverrini*   Stool microscopy           1807   14     15        1383      1792   ★★    \-   \-   \[[@pone.0132673.ref048]\]
                                 Itoh M           1994   Thailand    *Opisthorchis viverrini*   Serologic test             67     42     47        0         20     ★★★   ★    ★★   \[[@pone.0132673.ref044]\]
                                 Shin HR          1996   Korea       *Clonorchis sinensis*      Stool microscopy           386    12     36        44        350    ★★    ★★   ★★   \[[@pone.0132673.ref036]\]
                                 Shin HR          1996   Korea       *Clonorchis sinensis*      Liver fluke history        447    3      41        21        406    ★★    ★★   ★    \[[@pone.0132673.ref036]\]
                                 Chen MF          2001   China       *Clonorchis sinensis*      Serologic test             85     3      6         1         79     ★     ★    ★★   \[[@pone.0132673.ref023]\]
                                 Honjo S          2005   Thailand    *Opisthorchis viverrini*   Serologic test             253    65     126       8         127    ★     ★★   ★★   \[[@pone.0132673.ref049]\]
                                 Choi D           2006   Korea       *Clonorchis sinensis*      Stool microscopy           244    3      122       5         122    ★★    ★★   ★★   \[[@pone.0132673.ref039]\]
                                 Choi D           2006   Korea       *Clonorchis sinensis*      Pathologic examination     148    13     74        8         74     ★★    ★★   ★★   \[[@pone.0132673.ref039]\]
                                 Choi D           2006   Korea       *Clonorchis sinensis*      Serologic test             328    25     164       11        164    ★★    ★★   ★★   \[[@pone.0132673.ref039]\]
                                 Choi D           2006   Korea       *Clonorchis sinensis*      Skin test                  276    19     138       12        138    ★★    ★★   ★★   \[[@pone.0132673.ref039]\]
                                 Choi D           2006   Korea       *Clonorchis sinensis*      Radiological examination   370    156    185       57        185    ★★    ★★   ★★   \[[@pone.0132673.ref039]\]
                                 Lee TY           2008   Korea       *Clonorchis sinensis*      Stool microscopy           2869   26     619       9         2250   ★     ★★   ★★   \[[@pone.0132673.ref040]\]
                                 Poomphakwaen K   2009   Thailand    *Opisthorchis viverrini*   Stool microscopy           145    29     76        17        69     ★★★   ★★   ★★   \[[@pone.0132673.ref050]\]
                                 Cai WK           2011   China       *Clonorchis sinensis*      *Not mentioned*            921    4      313       1         608    ★     ★★   ★    \[[@pone.0132673.ref027]\]
                                 Peng NF          2011   China       *Clonorchis sinensis*      *Not mentioned*            294    18     98        19        196    ★★    ★★   ★    \[[@pone.0132673.ref028]\]
                                 Wang XP          2012   China       *Clonorchis sinensis*      *Not mentioned*            302    6      102       3         200    ★     ★★   ★    \[[@pone.0132673.ref029]\]
                                 Gao LB           2013   China       *Clonorchis sinensis*      Liver fluke history        640    2      128       2         512    ★     ★    ★    \[[@pone.0132673.ref030]\]
                                 Manwong M        2013   Thailand    *Opisthorchis viverrini*   Serologic test             246    110    123       99        123    ★★    ★★   ★★   \[[@pone.0132673.ref051]\]

The risk of hepatobiliary pathological changes associated with liver fluke infection {#sec014}
------------------------------------------------------------------------------------

### Cholangitis or cholecystitis {#sec015}

Several studies have reported a close association between liver fluke infection and cholangitis or cholecystitis \[[@pone.0132673.ref034], [@pone.0132673.ref052]\]. The overall RR with its 95% CI was extracted from the 3 included cohort studies\[[@pone.0132673.ref017], [@pone.0132673.ref018], [@pone.0132673.ref041]\], and the overall OR with its 95% CI was extracted from the 4 included case-control studies\[[@pone.0132673.ref022], [@pone.0132673.ref023], [@pone.0132673.ref043], [@pone.0132673.ref044]\]. The statistical heterogeneities of both the cohort studies and case-control studies were significant (I^2^ = 95%, P\<0.001 and I^2^ = 55%, P = 0.08, respectively); hence, the overall RR for the cohort studies and the overall OR for the case-control studies were estimated using a random-effects model. The analysis of the cohort studies and case-control studies revealed that liver fluke infection was significantly associated with cholangitis and cholecystitis. (RR: 7.80, 95% CI: 2.69--22.59, P\<0.001; OR: 15.98, 95% CI: 3.17--80.63, P\<0.001) (Figs [2](#pone.0132673.g002){ref-type="fig"} and [3](#pone.0132673.g003){ref-type="fig"}).

![Forest plot of cohort studies on the relationship between liver fluke infection and various hepatobiliary pathological changes.](pone.0132673.g002){#pone.0132673.g002}

![Forest plot of case-control studies on the relationship between liver fluke infection and various hepatobiliary pathological changes.](pone.0132673.g003){#pone.0132673.g003}

### Cholelithiasis {#sec016}

Liver fluke infection has been investigated as a risk factor for cholelithiasis\[[@pone.0132673.ref021]\]. In total, 8 cohort studies\[[@pone.0132673.ref017], [@pone.0132673.ref019]--[@pone.0132673.ref021], [@pone.0132673.ref032]--[@pone.0132673.ref034], [@pone.0132673.ref041]\] and 5 case-control studies\[[@pone.0132673.ref022], [@pone.0132673.ref023], [@pone.0132673.ref033], [@pone.0132673.ref035], [@pone.0132673.ref043]\] were used to perform the respective meta-analyses using a random-effects model (I^2^ = 97%, P\<0.001 and I^2^ = 75%, P\<0.001, respectively). The analyses yielded an RR of 2.42 (95% CI: 1.07--5.46, P = 0.03) and an OR of 4.96 (95% CI: 1.19--20.56, P = 0.03), indicating that infection with liver flukes is a risk factor for cholelithiasis and that the association is significant (Figs [2](#pone.0132673.g002){ref-type="fig"} and [3](#pone.0132673.g003){ref-type="fig"}).

### Cirrhosis {#sec017}

In total, 3 cohort studies\[[@pone.0132673.ref017], [@pone.0132673.ref033], [@pone.0132673.ref042]\] and 3 case-control studies\[[@pone.0132673.ref022], [@pone.0132673.ref023], [@pone.0132673.ref045]\] on cirrhosis and liver fluke infection were identified and used to perform meta-analyses. A random-effects model was applied to the analyses (I^2^ = 98%, P\<0.001 and I^2^ = 74%, P = 0.02, respectively). However, the result did not reveal a significant association between liver fluke infection and cirrhosis. For cohort studies, the overall RR of cirrhosis between infection with liver fluke and without infection was 3.50 (95% CI: 0.95--12.89, P = 0.06); for case-control studies, the overall OR of exposure to liver fluke infection between the case group and control group was 5.79 (95% CI: 0.83--40.28, P = 0.08) (Figs [2](#pone.0132673.g002){ref-type="fig"} and [3](#pone.0132673.g003){ref-type="fig"}).

### Hepatocellular carcinoma {#sec018}

Liver fluke infection has also been regarded as a risk factor for hepatocellular carcinoma \[[@pone.0132673.ref053]\]. Analysis of data from 6 case-control studies \[[@pone.0132673.ref022]--[@pone.0132673.ref026], [@pone.0132673.ref036]\] yielded inconsistent findings. The statistical heterogeneity was significant (I^2^ = 79%, P\<0.001); thus, a random-effects model was applied. According to the analysis of the case-control studies, hepatocellular carcinoma was significantly associated with liver fluke infection with an OR of 4.69 (95% CI: 2.32--9.49, P\<0.001) ([Fig 3](#pone.0132673.g003){ref-type="fig"}).

### Cholangiocarcinoma {#sec019}

The association between cholangiocarcinoma and liver fluke infection has been identified in articles over the last several decades \[[@pone.0132673.ref054], [@pone.0132673.ref055]\]. In our meta-analysis, 3 cohort studies\[[@pone.0132673.ref017], [@pone.0132673.ref033], [@pone.0132673.ref041]\] and 19 case-control studies\[[@pone.0132673.ref023], [@pone.0132673.ref027]--[@pone.0132673.ref031], [@pone.0132673.ref036]--[@pone.0132673.ref040], [@pone.0132673.ref043], [@pone.0132673.ref044], [@pone.0132673.ref046]--[@pone.0132673.ref051]\] were included. A fixed-effects model was used in the analysis of the cohort studies (I^2^ = 41%, P = 0.19), and a random-effects model was used (I^2^ = 77%, P\<0.001) in the analysis of the case-control studies. The overall RR for the association between liver fluke infection and cholangiocarcinoma was 10.43 (95% CI: 2.90--37.47, P\<0.001), and the association was significant. The overall OR for the association of cholangiocarcinoma with liver fluke infection was 4.37 (95% CI: 2.84--6.72, P\<0.001), which indicated that liver fluke infection was a risk factor for cholangiocarcinoma (Figs [3](#pone.0132673.g003){ref-type="fig"} and [4](#pone.0132673.g004){ref-type="fig"}).

![Forest plot of cohort studies on the relationship between liver fluke infection and cholangiocarcinoma.](pone.0132673.g004){#pone.0132673.g004}

Sensitivity analysis {#sec020}
--------------------

A sensitivity analysis was performed to identify whether the results of the meta-analysis were significantly affected by the exclusion of any individual study or the study with the highest quality or the greatest weight in the results. There was no significant impact observed in the overall ORs and 95% CIs.

Publication bias {#sec021}
----------------

Funnel plots of the studies in the meta-analysis were generated to evaluate publication bias (Figs [5](#pone.0132673.g005){ref-type="fig"} and [6](#pone.0132673.g006){ref-type="fig"}). For both cohort studies and case-control studies, the plots approximately resembled a symmetrical funnel, and no publication bias was found.

![Funnel plot of cohort studies to detect publication bias.](pone.0132673.g005){#pone.0132673.g005}

![Funnel plot of case-control studies to detect publication bias.](pone.0132673.g006){#pone.0132673.g006}

Meta-regression analyses {#sec022}
------------------------

Meta-regression analyses were generated to explore possible sources of heterogeneity. Our meta-regression showed that geographical area, decade of publication, liver fluke species and diagnostic method did not contribute significantly to the heterogeneity (Adjusted R^2^\<50% or P\>0.05) for either cohort studies or case-control studies. In contrast, for cohort studies only, the study sample size did have a contribution (Adjusted R^2^ = 73.13%, P\<0.001). The results of the meta-regression analyses are shown in [Table 3](#pone.0132673.t003){ref-type="table"}.

10.1371/journal.pone.0132673.t003

###### Results of the meta-regression analyses.

![](pone.0132673.t003){#pone.0132673.t003g}

  Study type             Factor                  Adjusted R^2^   P
  ---------------------- ----------------------- --------------- ---------
  Cohort studies         Area                    39.57%          0.009
                         Decade of publication   28.85%          0.023
                         Liver fluke species     -3.20%          0.475
                         Diagnostic methods      32.05%          0.015
                         Study sample size       73.13%          \<0.001
  Case-control studies   Area                    10.92%          0.007
                         Decade of publication   -2.46%          0.491
                         Liver fluke species     -3.20%          0.705
                         Diagnostic methods      -5.21%          0.822
                         Study sample size       -6.80%          0.75

Linear trend analyses of the dose-response relationship {#sec023}
-------------------------------------------------------

In total, 2 cohort studies\[[@pone.0132673.ref019], [@pone.0132673.ref041]\] and 3 case-control studies\[[@pone.0132673.ref025], [@pone.0132673.ref043], [@pone.0132673.ref050]\] with intensity groups (≥3) of liver fluke infection were included in the linear trend analysis to examine the relationship between infection intensity and incidences of hepatobiliary pathological changes ([Table 4](#pone.0132673.t004){ref-type="table"}). The results revealed a significant trend toward increasing incidences of hepatobiliary pathological changes with increasing intensity of liver fluke infection (P\<0.05).

10.1371/journal.pone.0132673.t004

###### Linear trend analysis.

![](pone.0132673.t004){#pone.0132673.t004g}

                                                                                                                            Test of linear trend              
  ---------------------- ------------------------------ -------------- ------ ------------------------- ----- ----- ------- ---------------------- ---------- ----------------------------
  Cohort studies         Cholangitis or cholecystitis   Mairiang       1992   1 (EPG^a^ = 0)            4     20    20.0%   16.598                 \< 0.001   \[[@pone.0132673.ref041]\]
                                                                              2 (EPG = 200 to 1000)     4     16    25.0%                                     
                                                                              3 (EPG = 2000 to 7000)    11    16    68.8%                                     
                                                                              4 (EPG \> 10000)          12    15    80.0%                                     
                         Cholelithiasis                 Mairiang       1992   1 (EPG = 0)               0     16    0.0%    4.983                  0.026      \[[@pone.0132673.ref041]\]
                                                                              2 (EPG = 200 to 1000)     2     14    14.3%                                     
                                                                              3 (EPG = 2000 to 7000)    3     8     37.5%                                     
                                                                              4 (EPG \> 10000)          1     4     25.0%                                     
                                                        Choi           2005   1 (EPG = 0)               9     169   5.3%    150.063                \< 0.001   \[[@pone.0132673.ref019]\]
                                                                              2 (EPG = 1 to 500)        54    532   10.2%                                     
                                                                              3 (EPG = 501 to 2000)     74    322   23.0%                                     
                                                                              4 (EPG ≥ 2001)            151   361   41.8%                                     
                         Cholangiocarcinoma             Mairiang       1992   1 (EPG = 0)               0     16    0.0%    7.827                  0.005      \[[@pone.0132673.ref041]\]
                                                                              2 (EPG = 200 to 1000)     0     12    0.0%                                      
                                                                              3 (EPG = 2000 to 7000)    0     5     0.0%                                      
                                                                              4 (EPG \> 10000)          2     5     40.0%                                     
  Case-control studies   Cholangitis or cholecystitis   Elikins        1990   1 (EPG = 0)               2     15    13.3%   5.321                  0.021      \[[@pone.0132673.ref043]\]
                                                                              2 (EPG = 1 to 500)        2     14    14.3%                                     
                                                                              3 (EPG = 501 to 2500)     2     11    18.2%                                     
                                                                              4 (EPG = 2501 to 10000)   1     4     25.0%                                     
                                                                              5 (EPG \> 10000)          5     9     55.6%                                     
                         Cholelithiasis                 Elikins        1990   1 (EPG = 0)               1     14    7.1%    4.711                  0.03       \[[@pone.0132673.ref043]\]
                                                                              2 (EPG = 1 to 500)        1     13    7.7%                                      
                                                                              3 (EPG = 501 to 2500)     0     9     0.0%                                      
                                                                              4 (EPG = 2501 to 10000)   1     4     25.0%                                     
                                                                              5 (EPG \> 10000)          3     7     42.9%                                     
                         Hepatocellular carcinoma       Tan            2007   1 (Years^b^ = 0)          415   902   46.0%   57.423                 \< 0.001   \[[@pone.0132673.ref025]\]
                                                                              2 (Years \< 10)           39    48    81.3%                                     
                                                                              3 (Years ≥ 10)            46    50    92.0%                                     
                         Cholangiocarcinoma             Elikins        1990   1 (EPG = 0)               0     13    0.0%    12.306                 \< 0.001   \[[@pone.0132673.ref043]\]
                                                                              2 (EPG = 1 to 500)        0     12    0.0%                                      
                                                                              3 (EPG = 501 to 2500)     2     11    18.2%                                     
                                                                              4 (EPG = 2501 to 10000)   2     5     40.0%                                     
                                                                              5 (EPG \> 10000)          4     8     50.0%                                     
                                                        Poomphakwean   2009   1 (EPG = 0)               47    99    47.5%   4.353                  0.037      \[[@pone.0132673.ref050]\]
                                                                              2 (EPG = 1 to 1000)       13    24    54.2%                                     
                                                                              3 (EPG \> 1000)           16    22    72.7%                                     

Discussion {#sec024}
==========

Several published studies \[[@pone.0132673.ref052], [@pone.0132673.ref056], [@pone.0132673.ref057]\] have reported an association between liver fluke infection and various hepatobiliary pathological changes, including cholangitis, cholecystitis, cholelithiasis, cirrhosis, hepatocellular carcinoma and cholangiocarcinoma. However, these published studies have not identified consistent findings for the risk of these hepatobiliary pathological changes and liver fluke infection. In this systematic review and meta-analysis of cohort studies and case-control studies, significant associations were found between liver fluke infection and cholangitis or cholecystitis (RR: 7.80, 95% CI: 2.69--22.59, P\<0.001; OR: 15.98, 95% CI: 3.17--80.63, P\<0.001), cholelithiasis (RR: 2.42, 95% CI: 1.07--5.46, P = 0.03; OR: 4.96, 95% CI: 1.19--20.56, P = 0.03), hepatocellular carcinoma (OR: 4.69, 95% CI: 2.32--9.49, P\<0.001) and cholangiocarcinoma (RR: 10.43, 95% CI: 2.90--37.47, P\<0.001; OR: 4.37, 95% CI: 2.84--6.72, P\<0.001). However, cirrhosis was not significantly associated with liver fluke infection (RR: 3.50, 95% CI: 0.95--12.89, P = 0.06; OR: 5.79, 95% CI: 0.83--40.28, P = 0.08). The observed statistical heterogeneity was significant, although sensitivity analysis did not alter the overall RR, overall OR, or their 95% CIs, and there was no evidence of publication bias.

A random-effects model was used in all of the analyses (except the analysis of cohort studies in cholangiocarcinoma) because significant heterogeneity was observed. Meta-regression analyses showed that the study sample size contributed significantly to the heterogeneity of the cohort studies (Adjusted R^2^ = 73.13%, P\<0.001); as interpreted, the study sample size could explain 73.13% of the heterogeneity. In contrast, geographical area, decade of publication, liver fluke infection and diagnostic methods did not contribute to the heterogeneity. This result is most likely related to the limited information included in the studies, such as study design, the stages of pathological changes, and other demographic characteristics.

In this systematic review and meta-analysis, we found that liver fluke infection was significantly associated with increased risk of cholangitis and cholecystitis. The liver fluke secretes metabolites while invading, some of which are highly immunogenic, stimulating a strong humoral immune response that can be measured in the serum and bile\[[@pone.0132673.ref058]\]. Another study revealed that *Opisthorchis* antigens were observed along with an inflammatory cell infiltration, and the antigens were not only in the fluke itself but also in the biliary epithelium and surrounding tissue, which might then activate host immune responses\[[@pone.0132673.ref059]\].

Our study confirmed that liver fluke infection was significantly associated with cholelithiasis. The cause of clonorchiasis was most likely related to changes in the concentration of bilirubin, cholesterol, phospholipids, bile acid and the core of the gallstone formed from parasite debris or epithelial cells from the biliary ducts\[[@pone.0132673.ref060]\]. The metaplasia of bile duct epithelial cells into goblet cells and mucin secretion occurs in clonorchiasis and promotes a favorable environment for secondary bacterial infection\[[@pone.0132673.ref061]\].

A positive association was found between hepatocellular carcinoma and liver fluke infection. The mechanism of hepatocellular carcinoma in patients with liver fluke infection remains unknown. One possible mechanism is that epithelial ulceration and hyperplasia induced by the suckers of liver flukes induce stimulation of metabolites from the worms\[[@pone.0132673.ref062]\]. Secondary bacterial infection gives rise to periductal adenomatous hyperplasia and mucin secretion, which may result in hepatocellular carcinoma\[[@pone.0132673.ref062]\]. Another possible mechanism is that severin, a liver fluke excretory/secretory product, plays a key role in inhibiting apoptosis in human hepatocellular carcinoma cell lines and exacerbates hepatocellular carcinoma\[[@pone.0132673.ref063]\].

Our systematic review and meta-analysis confirm a significant relationship between infection with liver flukes and cholangiocarcinoma. The mechanisms by which liver flukes contribute to cholangiocarcinoma are multi-factorial\[[@pone.0132673.ref056]\] and include mechanical damage caused by the activities and movements of the worms, chronic inflammation, and the effects of parasite secretions\[[@pone.0132673.ref057]\].

This study confirms not only the relationship between liver fluke infection and various hepatobiliary pathological changes, such as cholangitis, cholecystitis, cholelithiasis, hepatocellular carcinoma and cholangiocarcinoma, but also the relationship between intensity of liver fluke infection and incidences of the hepatobiliary pathological changes. We found a significant trend toward increasing incidences of hepatobiliary pathological changes with increasing intensity of liver fluke infection. The ordinal intensity of liver fluke infection was analyzed by linear trend analyses instead of meta-analyses due to the limited sample size and the different ordinal scales used among the included studies. Additionally, information was too limited to generate analyses of the association between the intensity of liver fluke infection and the severity of pathological changes. However, in our included studies \[[@pone.0132673.ref041], [@pone.0132673.ref043]\], most cases of cholangiocarcinoma were identified from heavily infected patients, which supports the hypothesis that high pathogenicity relates to heavy parasite infection. The pathogenesis is due to the mechanical irritation by the flukes and some toxic substances produced by them\[[@pone.0132673.ref064]\].

Although published studies provided evidence to support the hypothesis that liver fluke infection is associated with cirrhosis \[[@pone.0132673.ref045]\], our analysis failed to provide sufficient evidence for this association. This inconsistency likely occurred because the studies that identified a relationship between cirrhosis and liver fluke were limited to animals, such as cattle, goats and sheep \[[@pone.0132673.ref065], [@pone.0132673.ref066]\]. In addition, most cirrhosis is associated with *Fasciola hepatica* infection \[[@pone.0132673.ref066], [@pone.0132673.ref067]\], which was not included in our analysis because of the absence of eligible studies.

Several limitations of our study deserve mention. First, non-English, non-Chinese studies were not included in our meta-analyses, which might have an impact on the overall results. Second, because of the limited number of studies involved and limited information on the studies, our study was not powered to perform subgroup analyses, which might provide reasons for the significant heterogeneity as well.

Conclusion {#sec025}
==========

In conclusion, our systematic review and meta-analysis found that liver fluke infection is associated with an increased risk of cholangitis, cholecystitis, cholelithiasis, hepatocellular carcinoma and cholangiocarcinoma, and more severe infection is associated with higher incidence. However, no significant evidence was found for the association between liver fluke infection and cirrhosis.
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